Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 14/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NQO1 | P15559 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.51 |
| ▸ | MGAM | O43451 | 6/20 | 0.50 |
| ▸ | SI | P14410 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21645800 | 0.83 | GAA (0.62) | GAAKDM4EALDH1A1LMNANQO1 | |
| SCHEMBL9526995 | 0.79 | NQO1 (0.75) | KDM4EALDH1A1LMNANQO1MEN1 | |
| SCHEMBL3988877 | 0.79 | GAA (0.57) | GAAKDM4EALDH1A1LMNANQO1 | |
| SCHEMBL1230426 | 0.77 | GAA (1.00) | GAAKDM4EALDH1A1LMNANQO1 | |
| SCHEMBL6810405 | 0.77 | GAA (0.69) | GAAKDM4EALDH1A1LMNANQO1 | |
| SCHEMBL7483002 | 0.73 | GAA (0.69) | GAAKDM4EALDH1A1LMNANQO1 | |
| SCHEMBL94134 | 0.73 | GAA (0.69) | GAAKDM4EALDH1A1LMNAMAPK1 | |
| SCHEMBL28320998 | 0.73 | GAA (0.69) | GAAKDM4EALDH1A1LMNANQO1 | |
| SCHEMBL6810404 | 0.73 | GAA (0.69) | GAAKDM4EALDH1A1LMNANQO1 | |
| SCHEMBL21645801 | 0.72 | GAA (0.62) | GAAKDM4EALDH1A1LMNANQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250147026-A1 | BCR-ABL VARIANTS | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2025-05-08 | — | — | US | disclosed |
| US-12153049-B2 | BCR-ABL variants | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2024-11-26 | — | — | US | disclosed |
| US-20220196665-A1 | BCR-ABL VARIANTS | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2022-06-23 | — | — | US | disclosed |
| US-11275088-B2 | BCR-ABL variants | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2022-03-15 | — | — | US | disclosed |
| US-7879574-B2 | Folded peptide backbone each end of which is conjugated to a fluorophore, which when cleaved as by digestion with a protease, the fluorophores provide high intensity signals; histology | ONCOIMMUNIN, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090325168-A1 | HOMO-DOUBLY LABELED COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES | ONCOIMMUNIN, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-0988394-B1 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF | ONCOIMMUNIN INC (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7541143-B2 | Homo-doubly labeled compositions for the detection of enzyme activity in biological samples | ONCOIMMUNIN, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080199898-A1 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF | ONCOIMMUNIN, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7312302-B2 | Compositions for the detection of enzyme activity in biological samples and methods of use thereof | ONCOLMMUNIN, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20030207264-A1 | Homo-doubly labeled compositions for the detection of enzyme activity in biological samples | ONCOLMMUNIN, INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1356084-A2 | HOMO-DOUBLY LABELED COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES | ONCOIMMUNIN, INC. (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-0988394-A4 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF | ONCOIMMUNIN INC (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002061038-A9 | HOMO-DOUBLY LABELED COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES | ONCOIMMUNIN INC (US) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002061038-A2 | HOMO-DOUBLY LABELED COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES | ONCOIMMUNIN, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-1214445-A1 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF | ONCOIMMUNIN, INC. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001018238-A1 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF | ONCOIMMUNIN, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| EP-0988394-A1 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF | ONCOIMMUNIN, INC. (US) | 2000-03-29 | — | — | EP | disclosed |
| US-6037137-A | FLUORESCENT COMPOUND FOR SCREENING CLEAVING ACTIVITY AND STRUCTURAL CHANGES OF ENZYMATIC PROTEINS | ONCOIMMUNIN, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1998037226-A1 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF | ONCOIMMUNIN, INC. (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207264-A1 | Homo-doubly labeled compositions for the detection of enzyme activity in biological samples | DNTT, HMBS, WRN | GAA 603/4885KDM4E 3052/4885ALDH1A1 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.